These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18326010)

  • 21. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
    Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
    J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours.
    Laakso M; Tanner M; Isola J
    J Pathol; 2006 Sep; 210(1):3-9. PubMed ID: 16823892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.
    Isola J; Tanner M; Forsyth A; Cooke TG; Watters AD; Bartlett JM
    Clin Cancer Res; 2004 Jul; 10(14):4793-8. PubMed ID: 15269154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.
    Mehrazma M; Kalantari E; Rezvani H; Bahar B; Basi A; Razavi SM; Rakhshani N
    Asian Pac J Cancer Prev; 2015; 16(17):7695-700. PubMed ID: 26625783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections?
    Sumiyoshi K; Shibayama Y; Akashi S; Nohara T; Iwamoto M; Kobayashi T; Nishimura H; Yoshinaka R; Harada T; Tanigawa N
    Oncol Rep; 2006 Apr; 15(4):803-8. PubMed ID: 16525662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER 2 status in invasive breast cancer: immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization.
    Shirsat HS; Epari S; Shet T; Bagal R; Hawaldar R; Desai SB
    Indian J Pathol Microbiol; 2012; 55(2):175-9. PubMed ID: 22771638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
    Villman K; Sjöström J; Heikkilä R; Hultborn R; Malmström P; Bengtsson NO; Söderberg M; Saksela E; Blomqvist C
    Acta Oncol; 2006; 45(5):590-6. PubMed ID: 16864174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.
    Sartelet H; Lagonotte E; Lorenzato M; Duval I; Lechki C; Rigaud C; Cucherousset J; Durlach A; Graesslin O; Abboud P; Doco-Fenzy M; Quereux C; Costa B; Polette M; Munck JN; Birembaut P
    J Clin Pathol; 2005 Aug; 58(8):864-71. PubMed ID: 16049291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.
    Li-Ning-T E; Ronchetti R; Torres-Cabala C; Merino MJ
    Int J Surg Pathol; 2005 Oct; 13(4):343-51. PubMed ID: 16273190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.
    van de Vijver M; Bilous M; Hanna W; Hofmann M; Kristel P; Penault-Llorca F; Rüschoff J
    Breast Cancer Res; 2007; 9(5):R68. PubMed ID: 17922920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.
    Riethdorf S; Hoegel B; John B; Ott G; Fritz P; Thon S; Loening T; Pantel K
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):261-9. PubMed ID: 20396915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.
    Shousha S; Peston D; Amo-Takyi B; Morgan M; Jasani B
    Histopathology; 2009 Jan; 54(2):248-53. PubMed ID: 19207950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer.
    Hauser-Kronberger C; Dandachi N
    J Mol Histol; 2004 Aug; 35(6):647-53. PubMed ID: 15614619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.
    Di Palma S; Collins N; Faulkes C; Ping B; Ferns G; Haagsma B; Layer G; Kissin MW; Cook MG
    J Clin Pathol; 2007 Sep; 60(9):1067-8. PubMed ID: 17293390
    [No Abstract]   [Full Text] [Related]  

  • 37. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
    Shen DH; Wang FH; Yu YZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods.
    Bartlett JM; Starczynski J; Atkey N; Kay E; O'Grady A; Gandy M; Ibrahim M; Jasani B; Ellis IO; Pinder SE; Walker RA
    J Clin Pathol; 2011 Aug; 64(8):649-53. PubMed ID: 21690244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.
    Wixom CR; Albers EA; Weidner N
    Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):248-51. PubMed ID: 15551739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer.
    Arnould L; Denoux Y; MacGrogan G; Penault-Llorca F; Fiche M; Treilleux I; Mathieu MC; Vincent-Salomon A; Vilain MO; Couturier J
    Br J Cancer; 2003 May; 88(10):1587-91. PubMed ID: 12771927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.